The value of drug concentration and anti-drug antibody monitoring in biologic therapy for inflammatory bowel disease
10.3760/cma.j.cn114452-20230925-00167
- VernacularTitle:药物浓度及抗药抗体监测在炎症性肠病生物制剂治疗中的价值
- Author:
Minhu CHEN
1
;
Fei CHEN
Author Information
1. 中山大学附属第一医院消化内科，广州510080
- Keywords:
Inflammatory bowel disease;
Biologic agents;
Therapeutic drug monitoring
- From:
Chinese Journal of Laboratory Medicine
2023;46(11):1128-1133
- CountryChina
- Language:Chinese
-
Abstract:
Inflammatory bowel disease (IBD) is a chronic relapsing autoimmune disorder of the gastrointestinal tract. In recent years, biologic agents have been widely used in the treatment of IBD, significantly ameliorating symptoms in affected individuals. However, immunogenicity of these medications remains a limiting factor in IBD biologic therapy. The appropriate drug concentration is of great significance in improving the efficacy of biological agents, reducing the production of anti-drug antibodies, and reducing adverse reactions. Therefore, monitoring drug trough concentrations and anti-drug antibody levels during treatment can optimize medication usage and facilitate more informed adjustments to treatment strategies. This article elaborates on the mechanism and reasons for the generation of anti-drug antibodies, as well as the significance, timing, effectiveness, and detection methods of drug concentration and anti-drug antibody monitoring. Thus, it underscores the value of drug concentration and anti-drug antibody monitoring in the context of biologic therapy for IBD.
